Research programme: non-nucleoside reverse transcriptase inhibitors - Johnson & Johnson

Drug Profile

Research programme: non-nucleoside reverse transcriptase inhibitors - Johnson & Johnson

Alternative Names: HIV-1 therapeutics - Johnson & Johnson; NNRTIs - Johnson & Johnson

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Class Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported HIV-1 infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-1-infections in USA
  • 30 Mar 2007 Preclinical trials in HIV-1 infections in USA (unspecified route)
  • 30 Mar 2007 Preclinical data presented at the 233rd American Chemical Society National Meeting (ACS-2007) added to the Viral Infections pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top